Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Arthur Reitman

Interventional Cardiology Marietta, GA Medical Doctor

NPI 1184692691 CMS profile 325376

55 Whitcher St Ne, Suite 350, Marietta, GA 30060

Open in the dashboard

General payments

$105,656

676 records reported · program years 2019–2025

Research payments

$1,575

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$169,598 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Arthur Reitman of Marietta, GA is reported in the CMS Open Payments database as having received $105,656 across 676 general payments and $1,575 in research payments paid to them. Separately, studies naming them as principal investigator received $169,598 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 92nd percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,011 44
2024 General $3,664 92
2023 General $12,570 110
2022 General $11,220 110
2022 Research $1,575 1
2021 General $13,887 72
2020 General $16,867 85
2019 General $38,437 163

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Arthur Reitman
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Arthur Reitman were reported at $9,011. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Arthur Reitman Interventional Cardiology median Middle half National median
2019 $38,437 $1,097 $329–$3,048 $163
2020 $16,867 $473 $161–$1,480 $114
2021 $13,887 $677 $233–$1,827 $132
2022 $11,220 $978 $333–$2,724 $149
2023 $12,570 $1,136 $382–$2,986 $160
2024 $3,664 $1,181 $395–$3,326 $164
2025 $9,011 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $69,515 208 payments
  2. Medtronic Vascular, Inc. $11,829 54 payments
  3. Medtronic, Inc. $5,701 98 payments
  4. Abiomed $4,313 12 payments
  5. Abbott Laboratories $2,923 81 payments
  6. Shockwave Medical, Inc $2,645 30 payments
  7. Edwards Lifesciences Corporation $1,548 43 payments
  8. Philips Electronics North America Corporation $1,172 6 payments
  9. Siemens Medical Solutions USA, Inc. $674 7 payments
  10. Teleflex LLC $604 5 payments
  11. Other $4,733 132 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $29,475 11 payments
  2. Food and Beverage $27,922 591 payments
  3. Travel and Lodging $22,634 64 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $22,625 9 payments
  5. Honoraria $3,000 1 payment
Products named General payments · program years 2019–2025
  1. GENERAL VASCULAR ACCESS $17,808 13 payments
  2. CoreValve Evolut $9,812 30 payments
  3. General - Balloons $4,375 2 payments
  4. GENERAL THERAPIES $4,369 24 payments
  5. Impella $4,190 11 payments
  6. GENERAL - VASCULAR ACCESS $4,036 2 payments
  7. GENERAL - STRUCTURAL HEART $3,834 4 payments
  8. GENERAL STRUCTURAL HEART $3,739 6 payments
  9. ROTABLATOR $3,500 1 payment
  10. GENERAL ULTRASOUND $3,000 1 payment
  11. Other $35,824 555 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic, Inc. $1,575 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 38 drugs

Part D claims

1,711

Median for Interventional Cardiology: 2,236

Drug cost

$267,655

Median for Interventional Cardiology: $380,412

Branded share of claims

27.4%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 89 $105,138
Xarelto Rivaroxaban Brand 28 $36,829
Repatha Sureclick Evolocumab Brand 51 $32,516
Entresto Sacubitril/Valsartan Brand 22 $31,204
Jardiance Empagliflozin Brand 25 $26,200
Praluent Pen Alirocumab Brand 17 $15,893
Ranolazine Er Ranolazine Brand 16 $2,456
Metoprolol Succinate Generic 131 $1,949
Atorvastatin Calcium Generic 193 $1,760
Clopidogrel Clopidogrel Bisulfate Brand 122 $1,219

The 10 drugs with the highest cost, of 38 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 43 billing codes

Paid by Medicare

$87,051

Medicare's payments for the services billed

Medicare patients

271

Average age 78

Services billed

519

125 women, 146 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Arthritis 56%
Atrial fibrillation 50%
Heart failure 48%
Diabetes 42%
Chronic kidney disease 39%
COPD 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LEQVIO
$118 — —
XARELTO
$76 28 —
NEXLETOL
$66 — —
VERQUVO
$47 — —
CAMZYOS
$38 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

677 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record